Drug Trial Radar · NCT05364684
The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease
Last checked: Nov 19, 2026Latest source record: Jan 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Aug 10, 2022
Primary completion
Nov 22, 2024
Study completion Dec 23, 2024
Sponsor
- Lead sponsor
- Massachusetts General HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 6, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 21 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Nonalcoholic fatty liver disease (NAFLD), fatty infiltration of the liver in the absence of alcohol use, is an increasingly recognized complication of obesity, with prevalence estimates of about 30% of individuals in the United States. A subset of these will develop progressive disease in the form of nonalcoholic steatohepatitis (NASH), which can progress to cirrhosis and liver failure. The investigators hypothesize that LUM-201 (Ibutamoren mesylate) will decrease intrahepatic lipid accumulation as quantified by proton magnetic resonance spectroscopy (1H-MRS).
Conditions
- NAFLD
- Nonalcoholic Fatty Liver
- NASH - Nonalcoholic Steatohepatitis
Interventions
LUM-201Drug
LUM-201 (ibutamoren mesylate) is an oral growth hormone secretagogue.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Intrahepatic Lipid Content (IHL, Percent Liver Fat)Time frame: 6 Months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Massachusetts General Hospital
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.